Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Main Street Capital Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.44 (market cap $39.89B), while Main Street Capital Corporation trades at $52.95 (market cap $4.91B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 8.1× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 8.29% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MAIN | |
|---|---|---|
Market Cap | $39.89B | $4.91B |
Sector | Health | Financials |
52-Week High | $491.22 | $67.54 |
52-Week Low | $278.09 | $49.63 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 8.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Main Street Capital (MAIN) trades at $52.84, up 2.26% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with an 81.08% net margin and 14.37% ROE, though recent quarters show inconsistent earnings performance with two misses and one beat. Revenue declined slightly from $601M in 2024 to $592M in 2025, with further contraction projected for 2026. The stock pays consistent dividends, with recent payments ranging from $0.26 to $0.30 per share.
MAIN presents a cautious outlook with analysts showing 78.57% hold ratings despite a $57.75 consensus price target suggesting 9.3% upside. The bearish technical trend and projected revenue decline to $526M in 2026 create headwinds, while strong profitability metrics and dividend consistency provide support. Investors face balancing attractive valuation (P/E 11.12) against earnings volatility and negative operating cash flow of -$45.71M in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
